Jazz Pharma SVP receives 2,370 vested shares

Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock.

Rhea-AI Filing Summary

Jazz Pharmaceuticals executive Patricia Carr, who serves as SVP and Chief Accounting Officer, reported an acquisition of company stock. On January 16, 2026, she acquired 2,370 ordinary shares at a price of $0.0 per share. These shares will be delivered under performance share awards originally granted on March 3, 2023, after the company certified that the performance-based vesting requirements were satisfied on January 16, 2026. Following this award vesting, Carr now directly beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals.

Insider Trade Summary

Grant/Award: 2,370 shares

Grant/Award 1 txn

Insider Carr Patricia

Role SVP, Chief Accounting Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares	2,370	$0.00	$0.00

Holdings After Transaction: Ordinary Shares — 9,382 shares (Direct)

Footnotes (1)

1. F1. Represents ordinary shares of the Issuer that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Jazz Pharmaceuticals (JAZZ) report for Patricia Carr?

The filing shows that Patricia Carr, SVP and Chief Accounting Officer of Jazz Pharmaceuticals, acquired 2,370 ordinary shares on January 16, 2026 through the vesting of performance share awards.

How many Jazz Pharmaceuticals (JAZZ) shares does Patricia Carr own after this transaction?

After the reported transaction, Patricia Carr beneficially owns 9,382 ordinary shares of Jazz Pharmaceuticals directly.

What was the price per share for Patricia Carr’s Jazz Pharmaceuticals stock acquisition?

The 2,370 ordinary shares acquired by Patricia Carr were reported at a price of $0.0 per share, reflecting delivery under previously granted equity awards rather than an open-market purchase.

What triggered the vesting of Patricia Carr’s Jazz Pharmaceuticals performance share awards?

The vesting was triggered when the performance-based vesting requirements for the awards were satisfied and the level of performance attained was certified on January 16, 2026.

When were the Jazz Pharmaceuticals performance share awards granted to Patricia Carr?

The performance share awards underlying the 2,370 ordinary shares were granted to Patricia Carr on March 3, 2023.

Is Patricia Carr a director or major shareholder of Jazz Pharmaceuticals (JAZZ)?

According to the filing, Patricia Carr is an officer of Jazz Pharmaceuticals, serving as SVP, Chief Accounting Officer, and is not listed as a director or 10% owner.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/21/2026 - 08:39 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Carr Patricia

(Last) (First) (Middle)

5TH FL, WATERLOO EXCHANGE

WATERLOO RD

(Street)

DUBLIN 4 L2

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Jazz Pharmaceuticals plc [ JAZZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares	01/16/2026		A(1)		2,370	A	$0.0	9,382	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents ordinary shares of the Issuer that will be delivered pursuant to the terms of performance share awards made to the reporting person on March 3, 2023. The performance-based vesting requirements applicable to such awards were satisfied on January 16, 2026, which represents the date on which the level of performance attained was certified.

	By: /s/Paz Dizon as attorney in fact For: Patricia Carr	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.